United Therapeutics
Price
Price
Frequently asked questions
What is United Therapeutics's market capitalization?
What is United Therapeutics's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for United Therapeutics?
What are the analyst ratings and target price for United Therapeutics's stock?
What is United Therapeutics's revenue over the trailing twelve months?
What is the EBITDA for United Therapeutics?
What is the free cash flow of United Therapeutics?
What is the 5-year beta of United Therapeutics's stock?
How many employees does United Therapeutics have, and what sector and industry does it belong to?
What is the free float of United Therapeutics's shares?
Financials
Market Cap
$16.40B5Y beta
0.55EPS (TTM)
$22.75Free Float
43.82MP/E ratio (TTM)
16.15Revenue (TTM)
$2.76BEBITDA (TTM)
$1.41BFree Cashflow (TTM)
$898.10MPricing
Analyst Ratings
The price target is $302.75 and the stock is covered by 15 analysts.
Buy
12
Hold
2
Sell
1
Information
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
1,168
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker